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Background: Chlorhexidine digluconate (CHG) is a widely used skin antiseptic, however it poorly penetrates the
skin, limiting its efficacy against microorganisms residing beneath the surface layers of skin. The aim of the current
study was to improve the delivery of chlorhexidine digluconate (CHG) when used as a skin antiseptic.
Method: Chlorhexidine was applied to the surface of donor skin and its penetration and retention under different
conditions was evaluated. Skin penetration studies were performed on full-thickness donor human skin using a
Franz diffusion cell system. Skin was exposed to 2% (w/v) CHG in various concentrations of eucalyptus oil (EO) and
70% (v/v) isopropyl alcohol (IPA). The concentration of CHG (μg/mg of skin) was determined to a skin depth of
1500 μm by high performance liquid chromatography (HPLC).
Results: The 2% (w/v) CHG penetration into the lower layers of skin was significantly enhanced in the presence of
EO. Ten percent (v/v) EO in combination with 2% (w/v) CHG in 70% (v/v) IPA significantly increased the amount of
CHG which penetrated into the skin within 2 min.
Conclusion: The delivery of CHG into the epidermis and dermis can be enhanced by combination with EO, which
in turn may improve biocide contact with additional microorganisms present in the skin, thereby enhancing
antisepsis.
Background
Chlorhexidine (CHG) is a broad spectrum antimicrobial
agent widely used for skin antisepsis prior to invasive pro-
cedures. However, the efficacy of CHG is reduced in the
presence of organic matter and at low pH [1]. Further-
more, CHG, as with other antiseptic preparations exhibits
restricted penetration through the skin; our previous stu-
dies demonstrate that CHG from aqueous and alcoholic
[70% (v/v) isopropyl alcohol (IPA)] solutions poorly pene-
trate the full thickness skin to the deeper skin layers [2,3].
This limits its efficacy against microorganisms residing in
the lower layers of the epidermis and dermis, including
hair follicles and sebaceous glands [2-6]. These persisting
microorganisms, which include coagulase negative staphy-
lococci, anaerobic bacteria such as Propionibacterium spp.,
and yeast Candida spp., may subsequently cause infection
when the protective skin barrier is breached during
surgical procedures [7-10]. These microorganisms may
also contaminate invasive medical devices such as intra-
vascular catheters when they are passed through the skin,
and thereby result in infection [11]. This residual source of
microorganisms also offers ane x p l a n a t i o nf o rt h er e l a -
tively high incidence of surgical site infections which
occurs despite the scrupulous use of currently available
skin antiseptics. Indeed, an estimated 5% of patients who
have undergone a surgical procedure develops a surgical
site infection [12]. Novel strategies to enhance the pene-
tration of antiseptic agents into the skin, thereby improv-
ing their efficacy against microorganisms located in the
epidermis and dermis are therefore needed if these infec-
tions are to be prevented
Developments in the transdermal delivery of drugs
offer a potential solution to improvement in the pene-
tration of antiseptic agents into the skin. One such
approach has been the application of essential oils, such
as eucalyptus oil (EO), which contains terpenes [13].
Eucalyptus oil is an effective skin penetration enhancer
and it contains 1,8-cineole, a monoterpene cyclic ether,
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hydrophilic compounds [14-17]. Terpenes, including
1,8-cineole, bind to the stratum corneum (SC) and are
thought to enhance lipophilic drug penetration by
increasing the partition coefficient and hydrophilic drug
penetration by increasing the diffusion coefficient
[18,19]. 1,8-cineole has been found to increase skin
penetration by disrupting intercellular lipids in SC and
to change SC membrane fluidity at the concentrations
as low as 1% to 5% [16,17,19-22]. Yamane et al. [17]
however showed that the effect of lipid disruption was
reversible and that 1,8-cineole did not result in lipid
depletion from the SC.
Essential oils have also a broad spectrum of antimicro-
bial activity and this property has been harnessed in
therapeutics, including skin cleansing (MRSA decoloni-
sation) and treatment of necrotic ulcers [23-25]. Euca-
lyptus oil may therefore serve as a suitable candidate for
enhancing the delivery of CHG into the skin, including
hair follicles and sebaceous glands, where many micro-
organisms reside. The presence of EO may also enhance
the antimicrobial activity of CHG, as the combination
has been shown to have synergistic antimicrobial activity
against bacteria [26]. The aim of the current study was
to evaluate the skin penetration of CHG and its reten-
tion at various depths of skin in the presence of EO.
Methods
Materials
Sodium heptane sulphonate, diethylamine (both high-
performance liquid chromatography [HPLC] grade),
phosphate buffered saline (PBS) tablets, aqueous 20%
(w/v) CHG, eucalyptus oil (EO) (containing 82.9%
cineole) and isopropyl alcohol (IPA) were purchased
from Sigma-Aldrich (Dorset, UK). Phosphate buffered
saline (Sigma-Aldrich, Dorset, UK) was reconstituted
from tablets according to manufacturers’ instructions.
Methanol and glacial acetic acid (all HPLC grade) were
purchased from Fisher Scientific (Leicestershire, UK).
Skin samples
Full thickness human skin samples were obtained from
three patients undergoing breast reduction surgery and
who consented their excised skin for ethically approved
research study. The donor skin was frozen on the day of
excision and stored at -70°C until required. Full ethical
committee approval was obtained prior to this study
from South Birmingham Research Ethics Committee.
Quantification of CHG
High-performance liquid chromatography was used to
measure CHG in the skin samples obtained during the
penetration studies. The analyses were performed with an
Agilent 1200 series HPLC system (Agilent Technologies,
UK). The samples were run at a flow rate of 1.2 mL/min
at room temperature through a reverse phase chromato-
graphy column [CPS-2 Hypersil; dimension 150 × 4.6 mm,
5 μm particle size (Thermo Electron Corporation, UK)]
with ultraviolet detection at a wavelength of 254 nm. The
isocratic mobile phase consisted of a methanol: water mix-
ture (75:25) with 0.005 M sodium heptane sulphonate and
0.1% (v/v) diethylamine adjusted to pH 4.0 with glacial
acetic acid. The method for CHG quantification by
HPLC was validated and the levels of detection (LOD)
and quantification (LOQ) were determined as previously
described [2].
CHG skin penetration profile studies
Skin penetration studies were performed with vertical
Franz diffusion cells as previously described [2]. In brief,
skin samples were mounted onto Franz diffusion cells
with the stratum corneum (SC) uppermost facing the
donor compartment. The receptor compartment was filled
with 29 mL of PBS maintained at 37°C). The skin was left
to equilibrate for 30 min to reach the temperature of 32°C
before application of the test solution (the surface area of
skin exposed to the test compound was 3.14 cm2).
Twenty percent (w/v) aqueous CHG was diluted with
distilled water, IPA and EO to obtain the final concentra-
tions of 2% (w/v) CHG with 5%, 10%, 20% and 50% (v/v)
EO and 10% (v/v) EO with 2% (w/v) CHG in 70% (v/v)
IPA. Tween 80 [0.1% (v/v)] was added to the test solu-
tions to enhance EO solubility in the vehicle. One mL of
each test solution was spread over a separate skin surface
in the donor compartment. Following a 2 min, 30 min
and 24 h exposure, skin samples were removed, washed
with PBS and sprayed with a cryospray (Bright Instru-
ments, Cambridgeshire, UK) and frozen at -20°C. Punch
biopsies (7 mm in diameter) were then cut from each fro-
zen sample in triplicate and the samples were sectioned
horizontally with a cryotome (Bright Instruments) into
20 μm sections (from the surface to a depth of 600 μm)
and 30 μm sections (from depths of 600 to 1500 μm).
Chlorhexidine was extracted from the skin by mobile
phase solution and analysed by HPLC (CHG extraction
was validated prior to the study as described previously)
[ 2 ] .T h ea m o u n t so fC H Gw e r ec a l c u l a t e da sμg per mg
of skin. Control skin (with no added CHG treatment)
was analysed parallel to the test samples. The assay was
performed in triplicate.
Determination of CHG permeation through the full
thickness skin
During the skin permeation studies 1 mL of receptor fluid
was removed every 30 min for 2 h, every hour between 2
to 6 h and at 8 h, 12 h and 24 h. Fluid removed from the
receptor compartment was immediately replaced with
an equal volume of fresh PBS solution. All samples were
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in triplicate.
Statistical analysis
The data obtained were analysed by a student t-test with
INSTAT3 software (Graph pad software version 3.06)
with a p < 0.05 level of significance.
Results
Chlorhexidine skin penetration following exposure to
CHG in combination with 50% (v/v) EO
Combining 2% (w/v) CHG with 50% (v/v) EO enhanced
penetration of CHG into the lower layers of skin within
2 min; the CHG concentrations achieved at depths of
300- 1500 μm were between 0.019 - 0.043 μgp e rm g
tissue (Figure 1). After 30 min the concentration of
CHG in the upper 100 μm, following application of 2%
(w/v) CHG with 50% (v/v) EO, was 0.398 (+/-0.076) μg
per mg tissue (Figure 1).
CHG skin penetration following exposure to CHG in
various concentrations of EO
The effect of different EO concentrations on CHG pene-
tration into the skin was evaluated over a 24-h period.
Five percent (v/v) EO facilitated greater CHG skin pene-
tration to the deeper layers of the skin (below 300 μm)
and 10% (v/v) EO enhanced CHG skin penetration in
the upper 900 μm. There were no significant differences
in CHG concentration achieved in the skin following
application of 2% (w/v) CHG with 10% (v/v) EO or 20%
(v/v) EO (Figure 2).
Chlorhexidine skin penetration with alcohol and EO
The optimum EO concentration, which enhanced CHG
penetration into the full thickness human skin, was
further evaluated in combination with 2% (w/v) CHG in
70% (v/v) IPA. Ten percent (v/v) EO in combination
with 2% (w/v) CHG in 70% (v/v) IPA demonstrated
enhanced CHG skin penetration after a 2-min and 30-
min exposure on the skin (Figure 3).
CHG penetration through the full thickness skin
Chlorhexidine was not detected in the receptor com-
partment (LOD 0.0157 μg/mL) during the 24 h skin
permeation study under any conditions when using full
thickness human skin (epidermis and dermis) from two
of three different donors. Less than 0.0016% of the
applied dose of CHG was detected during the skin
Figure 1 The amount of CHG (μg/mg of tissue) at increasing depths of excised human skin after a 2-min and 30-min exposure to 2%
(w/v) CHG in 50% (v/v) EO (mean ± SEM, n = 15).
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(w/v) CHG in combination with various concentrations of EO (mean ± SEM, n = 15).
Figure 3 The amount of CHG (μg/mg of tissue) at increasing depths of excised human skin after a 2-min (n = 10) and 30-min
exposure (n = 15) to 2% (w/v) CHG in 70% (v/v) IPA and 10% (v/v) EO (mean ± SEM).
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mL) following 24-h exposure to 2% (w/v) CHG with
50% (v/v) EO.
Discussion
In the current study penetration of CHG into the lower
layers of the epidermis and dermis was enhanced when
applied in combination with EO. This enhanced pene-
tration has the potential for improving skin antisepsis in
clinical practice by increasing the concentration of CHG
beneath the surface layers of skin where microorganisms
can reside. Indeed, the concentration of CHG within the
upper 100 μm of skin was increased from 0.023 (+/-
0.007) μg/mg of tissue (as presented in our previous
study [3]) to 0.121 (+/- 0.019) μg/mg of tissue after 2
min application of 2% (w/v) CHG in 70% (v/v) IPA and
10% (v/v) EO compared to CHG/IPA alone. Assuming
that 1 g of tissue is equal to 1 mL, these concentrations
of CHG achieved are higher than the minimum bacteri-
cidal concentration against many skin microorganisms
such as Staphylococcus epidermidis [ 2 6 ] .H o w e v e r ,a
microbial reservoir can reside in the deeper layers of the
skin (and sebaceous glands) following skin antisepsis [4],
which may contribute to high number of infections
associated with invasive procedures such as surgery or
insertion of intravascular catheters. Improved skin deliv-
ery of antiseptic agents may therefore enhance skin anti-
sepsis and reduce the risk of infection associated with
the invasive procedures and also intravascular catheters.
The use of 2% (w/v) CHG in EO may therefore reduce
the likelihood of re-seeding of microorganisms onto the
skin surface following skin antisepsis, thereby further
reducing the risk of infection.
Two percent (w/v) CHG in 70% (v/v) IPA is a recom-
mended antiseptic agent for central venous catheter
(CVC) insertion and CVC site care [27]. The skin penetra-
tion of CHG following application of 2% (w/v) CHG in
70% (v/v) IPA onto skin was however limited [3]. Chlor-
hexidine in alcohol has been shown to have superior anti-
microbial activity compared to 2% (w/v) aqueous CHG,
however their efficacy in reducing intravascular catheter
related infections and catheter colonisation are compar-
able [28-30]. Alcohol, at high concentrations, has a rapid
and broad spectrum of antimicrobial activity, but it has
been shown to extract SC lipids and dehydrate SC pro-
teins, therefore increasing the SC permeation barrier
[31-34]. However, combining 10% (v/v) EO with 2% (w/v)
CHG in 70% (v/v) IPA significantly enhanced CHG skin
penetration compared to CHG/IPA alone. Similar pre-
vious studies on terpenes in combination with ethanol
have shown increased skin permeation of diclofenac
sodium [35]. The application of CHG in alcohol and EO
seems to offer a solution for enhancing CHG skin penetra-
tion but still retaining its skin surface antiseptic activity.
Eucalyptus oil and chlorhexidine are currently used in
various pharmaceutical preparations, which are applied
to the skin and mucous membranes. These compounds
are regarded as safe with few reported adverse reactions.
Side effects of CHG have included contact dermatitis
and rarely hypersensitivity and anaphylaxis. In compari-
son, EO adverse reactions are less well known, however
7% EO has been used on necrotic neck ulcers (in com-
bination with other oils) without adverse reactions [25].
Regarding systemic reactions, in this current study CHG
was only detected at negligible levels in the receptor
compartment suggesting that CHG does not permeate
through the full skin thickness, and is retained within
the tissue. This property reduces the risk of systemic
adverse reaction. Indeed, these results further support
previous research on another CHG based compound,
chlorhexidine phosphanilate, which did not permeate
through the full thickness of skin [36]. Furthermore,
other studies have shown that cineole, which is the pre-
dominant terpene in EO, binds to SC and is retained in
the skin and does not permeate through the skin in in
vitro assays [18,19,37]. It would therefore appear that
both CHG and EO have a minimal risk of stimulating
systemic reactions as they poorly permeate the whole
skin. Further clinical studies on this are however
required to substantiate this.
Conclusions
In conclusion, the current study demonstrates that 2%
(w/v) CHG penetration into the deeper layers of skin
was significantly enhanced with EO compared to CHG
in aqueous solutions or in 70% (v/v) IPA. Furthermore,
2% (w/v) CHG in combination with 70% (v/v) IPA and
10% (v/v) EO significantly increased the amount of
CHG in the skin within 2 min compared to CHG/IPA.
These exciting results lay the foundation for further
research within this area with a view to potentially
adopting alternative strategies for enhanced skin anti-
sepsis in clinical practice. Further studies need to be
undertaken to determine the skin tolerance of EO and
the clinical efficacy of CHG in combination with EO in
reducing the number of infections associated with inva-
sive procedures such as insertion of intravascular
catheters.
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